While some work has been done to determine the impact of mood and anxiety disorders and its treatment on comorbidities, not much has been undertaken to determine their actual impact on other CD development. In light of the present results showing an increased risk in individuals with mood and anxiety disorders to develop diabetes, other mental disorders and asthma, as well as its consequences on other CD management and related complications, this study supports the development of new approaches to address this problem. In the present study, those with asthma at baseline were more likely to develop COPD and hypercholesterolemia. While asthma has a younger age of onset, it is also associated with higher comorbidity rates. In the present study, over 30% of those that developed more than two CDs developed both hypercholesterolemia and asthma which suggest an association between those two CDs. In support of this hypothesis, asthma has been related to a disorder in cholesterol ABT-199 metabolism. However, much work needs to be done to better understand and support this hypothesis. During the 7.8 years of follow-up, over 35% of the individuals with asthma developed COPD. This is in line with a recently reported overlapping in both asthma and COPD that could be associated with more frequent and severe respiratory exacerbations despite a younger age and a reduced lifetime smoking history. In the present study, the younger age observed in this population supports this observation. While data have been adjusted for risk factors such as age, sex, education, marital status, working status, annual income and BMI, some potential residual confounders, such as nutrition and sedentary lifestyle, could still have an impact on multimorbidity evolution. The number of CDs investigated in the present study is also relatively small when compared to some multimorbidity studies. However, the diagnosis of most of those CDs is based on biomedical measurement which is more precise than most other data sources since it Z-VAD-FMK Caspase inhibitor ensures consistency of measurement despite potential change in CD definition, identification and screening procedure.